Working… Menu

A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00422019
Recruitment Status : Completed
First Posted : January 15, 2007
Last Update Posted : April 10, 2015
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to evaluate the effectiveness and safety of AMG 102 in patients with Advanced Renal Cancer.

Condition or disease Intervention/treatment Phase
Advanced Renal Cell Carcinoma Drug: AMG 102 at 10 mg/kg Drug: AMG 102 at 20 mg/kg Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 61 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Global, Multicenter, Open-label, Single Agent, Two-stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects With Advanced Renal Cell Carcinoma
Study Start Date : January 2007
Actual Primary Completion Date : March 2009
Actual Study Completion Date : March 2009

Arm Intervention/treatment
Experimental: AMG 102 at 20 mg/kg Dose Level
Up to 40 subjects will be treated at 20 mg/kg of AMG 102 Q2W (every 2 weeks) depending upon the stage of the study and number of responses observed.
Drug: AMG 102 at 20 mg/kg
AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks

Experimental: AMG 102 at 10 mg/kg Dose Level
Up to 40 subjects will be dosed at 10mg/kg of AMG 102 Q2W (every two weeks) based upon the stage of the study and number of responses observed.
Drug: AMG 102 at 10 mg/kg
AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks

Primary Outcome Measures :
  1. To assess the objective response rate in subjects with advanced renal cell carcinoma receiving AMG 102 treatment [ Time Frame: 9 weeks from first dose of AMG 102 ]

Secondary Outcome Measures :
  1. To estimate the overall survival and progression free survival rates in this population [ Time Frame: 8 week intervals ]
  2. To assess the duration of response and time to response in this population [ Time Frame: treatment period ]
  3. To assess the pharmacokinetics of AMG 102 in subjects with advanced renal cell carcinoma [ Time Frame: Weeks 1, 5, and 9 ]
  4. To assess the safety profile of AMG 102 in subjects with advanced renal cell carcinoma [ Time Frame: entire study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • documented histologically confirmed advanced or metastatic renal cell carcinoma with the primary tumor in place or following nephrectomy
  • measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques (CT or MRI) or ≥ 10 mm by spiral CT scan
  • no more than 3 relapses (or prior systemic treatments)
  • unable to receive or failed prior therapy with vascular endothelial growth factor (VEGF) binding agents or VEGF receptor tyrosine kinase inhibitors or other multi-kinase inhibitors
  • tissue blocks or tissue sections from initial or upon diagnosis of advanced metastatic disease are available for submission to the central laboratory within approximately 4 weeks after enrollment or approval is granted by the sponsor (upon receipt of justification why the sample is not available)
  • age ≥ 18 years
  • ECOG performance status of 0-2
  • hemoglobin concentration ≥ 9 g/dL
  • absolute neutrophil count ≥ 1.5 x 10(9th)/L
  • corrected serum calcium ≤ 10 mg/dL
  • either serum creatinine < 2.0 x upper limit of normal OR creatinine clearance > 40 mL/min
  • alanine aminotransferase ≤ 2.5 times upper limit of normal or < 5.0 x ULN if the subject has documented liver metastasis or primary hepatic neoplasm
  • serum total bilirubin ≤ 2.5 times upper limit of normal
  • before any study-specific procedure, the appropriate written informed consent must be obtained

Exclusion Criteria:

  • active brain metastases; brain metastases allowed provided they have been treated with surgery and/or radiation therapy and show no evidence of progression on cerebral CT or MRI scan 2 months following surgery and/or radiation therapy
  • concurrent severe and/or uncontrolled medical disease (e.g., uncontrolled diabetes, congestive cardiac failure, myocardial infarction within 6 months before enrollment) that could compromise participation in the study
  • documented history of human immunodeficiency virus infection
  • documented history of viral chronic hepatitis
  • received biologic, small molecule, immunotherapy, chemotherapy, radiotherapy or other agents to treat renal cancer within 28 days before enrollment
  • treated previously with c-Met or HGF targeted therapy
  • concurrent or prior (within 7 days before enrollment) anticoagulation therapy, except:

    • Use of low-dose warfarin (< 2 mg/day) for prophylaxis against central venous catheter thrombosis or
    • Use of low molecular weight heparins (LMWH, e.g., enoxaparin sodium [Lovenox] and unfractionated heparin for prophylaxis against central venous catheter thrombosis is allowed
  • concurrent use of hormones or other chemotherapeutic agents except for steroids given for adrenal failure and hormones administered for non-disease-related conditions (eg, insulin for diabetes); except for non-cancer reasons
  • concurrent palliative or therapeutic radiation therapy
  • currently enrolled in or has not yet completed at least 30 days since ending other investigational device or therapy, or subject is receiving other investigational agent(s)
  • active infection requiring treatment within 1 week before enrollment
  • undergone major surgery within 4 weeks before enrollment or recovering from prior surgery
  • past or current history of another neoplasm, except for curatively treated non-melanoma skin cancer, carcinoma in situ of the cervix and other primary solid cancer with no known active disease present and no curative treatment administered for the last 3 years
  • known allergy or sensitivity to any of the excipients in the investigational product to be administered
  • pregnant or is breast feeding
  • not consenting to use adequate contraceptive precautions during the course of the study and for 6 months after the last administration of investigational product:

    • female subjects who are not post-menopausal (no menstrual period for a minimum of 12 months at study entry) or documented surgically sterile will not be bound to this exclusion
  • previously treated with AMG 102
  • previously enrolled into this study
  • will not be available for follow-up assessments
  • has other disorders that compromises the ability of the subject to give written informed consent and/or comply with study procedures
  • unable to begin protocol specified treatment within 3 days after enrollment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00422019

Sponsors and Collaborators
Layout table for investigator information
Study Director: MD Amgen
Additional Information:
Schöffski P, Garcia J, Stadler W, Gil T, Jonasch E, Tagawa S, Kabbinavar F.A phase 2 study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma.Journal-004247;2010 Dec 15; 1-8

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Amgen Identifier: NCT00422019    
Other Study ID Numbers: 20060100
First Posted: January 15, 2007    Key Record Dates
Last Update Posted: April 10, 2015
Last Verified: March 2015
Keywords provided by Amgen:
Renal Cancer
Kidney Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs